Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark |
| |
| Authors: | Trine Pilgaard Mikkel Hasse Pedersen Steen Hvitfeldt Poulsen |
| |
| Institution: | 1. Pfizer Denmark, Health and Value, Ballerup, Denmark Trine.Pilgaard@pfizer.com https://orcid.org/0000-0002-1771-956X;3. Incentive, Holte, Denmark https://orcid.org/0000-0002-3568-767X;4. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark https://orcid.org/0000-0002-9586-835X |
| |
| Abstract: | Abstract Aims Wild-type transthyretin amyloid cardiomyopathy (ATTRwt) is a fast progressing and fatal disease associated with substantial delays in diagnosis. Between the first symptoms and diagnosis, patients are frequently hospitalized, primarily with cardiac symptoms. After diagnosis, patients continue to experience frequent hospital admissions. The objective of this study was to estimate the Danish diagnostic and lifetime hospital costs associated with the treatment of patients with ATTRwt both before and after they are diagnosed. |
| |
| Keywords: | Amyloidosis cardiomyopathy costs transthyretin wild-type |
|
|
![ORCID Icon]({"type":"image","src":"/templates/jsp/images/orcid.png"} "ORCID Icon")
https://orcid.org/0000-0002-1771-956X;3. Incentive, Holte, Denmark